ACHV — Achieve Life Sciences, Inc.

ACHV Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics:

• Achieve Life Sciences closed a significant financing round, securing $180 million in upfront capital and up to $174 million from milestone-based warrants, positioning the company for future growth.

2. Strategic Updates and Business Highlights:

• Dr. Andrew Goldberg has taken over as CEO, emphasizing a mission-driven approach to develop cytisinicline for smoking and vaping cessation.
• The company has partnered with Adare Pharma Solutions for the manufacturing of cytisinicline, producing its first engineering batch in Q1 2026.
• Achieve plans to resubmit its New Drug Application (NDA) in Q4 2026, with expectations for a commercial launch in the first half of 2027.
• Recent clinical data published indicates cytisinicline's efficacy, particularly among patients who have previously failed other treatments.

3. Forward Guidance and Outlook:

• The company aims to finalize its NDA resubmission by Q4 2026 and is preparing for a commercial launch in early 2027.
• Dr. Goldberg expressed confidence in meeting timelines, emphasizing proactive measures and transparency with investors.
• The commercial strategy will focus on independent commercialization with a dedicated field force, leveraging the new leadership team's experience.

4. Bad News, Challenges, or Points of Concern:

• Achieve expects to receive a complete response letter from the FDA by June 20, 2026, due to issues at a previous third-party manufacturer, which could delay the NDA resubmission.
• There are concerns regarding the competitive landscape, with emerging therapies for smoking cessation potentially impacting market dynamics.
• The transition to a new manufacturing partner raises risks related to meeting demand and maintaining timelines.

5. Notable Q&A Insights:

• Dr. Goldberg reassured investors about the durability of cytisinicline's intellectual property and the company's readiness to meet regulatory timelines.
• He acknowledged the importance of building awareness among prescribers and the need for effective patient support programs at launch.
• Questions about the size of the sales force and the timing of the vaping Phase III trial were addressed, indicating a cautious but strategic approach to scaling operations.
• The company is committed to generating additional data to support its market position and is exploring unique subsets within the smoking community for future studies.

Overall, Achieve Life Sciences is positioned for growth with a strong capital foundation and strategic leadership, but faces regulatory hurdles and competitive pressures in the smoking cessation market.